Phase II Trial of Murine Monoclonal Antibody D612 Combined with Recombinant Human Monocyte Colony-stimulating Factor (rhM-CSF) in Patients with Metastatic Gastrointestinal Cancer

Mansoor N. Saleh, M. B. Khazaeli, Richard H. Wheeler, Tiepu Liu, Michael P. Everson, Albert F. LoBuglio, R. Pat Bucy, Jeff Schlom, David H Munn

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

In a Phase II study, 14 patients with metastatic gastrointestinal cancer received the mAb D612 (40 mg/m2, days 4,7, and 11) in combination with recombinant human monocyte colony-stimulating factor [(rhM-CSF) 80 ug/kg/days 1–14]. The combined treatment was well tolerated and resulted in characteristic biological activity associated with each of the agents. Thus, 10 of 14 patients experienced D612-associated secretory diarrhea, which responded to the prostaglandin inhibitor Indomethacin in 5 of 7 patients. rhM-CSF therapy was associated with peripheral monocytosis (peak absolute monocyte count, 1444 ± 394/mm3) and thrombocytopenia (nadir count, 78 ± 10/mm3). Monocyte surface marker analysis revealed a high baseline expression of CD16+ cells in our patient population with an additional increase with rhM-CSF therapy. We observed a correlation between the degree of thrombocytopenia and the pretreatment CD16+ monocyte count Of the plasma cytokines assayed, serum Neop-terin demonstrated the most consistent increase during rhM-CSF therapy. There was a significant difference in the half-life of the first and last dose of D612 (35.8 ± 2 versus 27 ± 2.9 h; P < 0.05). Eleven of fourteen patients developed low-moderate levels of anti-D612 antibody. Despite the observed biological activity of both rhM-CSF and D612 and the previously described in vitro synergy, no clinical antitumor responses were observed in this Phase II study.

Original languageEnglish (US)
Pages (from-to)4339-4346
Number of pages8
JournalCancer Research
Volume55
Issue number19
StatePublished - Oct 1 1995

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II Trial of Murine Monoclonal Antibody D612 Combined with Recombinant Human Monocyte Colony-stimulating Factor (rhM-CSF) in Patients with Metastatic Gastrointestinal Cancer'. Together they form a unique fingerprint.

  • Cite this

    Saleh, M. N., Khazaeli, M. B., Wheeler, R. H., Liu, T., Everson, M. P., LoBuglio, A. F., Bucy, R. P., Schlom, J., & Munn, D. H. (1995). Phase II Trial of Murine Monoclonal Antibody D612 Combined with Recombinant Human Monocyte Colony-stimulating Factor (rhM-CSF) in Patients with Metastatic Gastrointestinal Cancer. Cancer Research, 55(19), 4339-4346.